In a recent phase I/II clinical trial, a specific ASO showed good results in treating Leber congenital amaurosis 10, Usher syndrome type 2 and (rhodopsin) RHO-associated autosomal-dominant retinitis pigmentosa [188]. This evidence concerns the gene RHO and Usher syndrome type 2.